CA Patent

CA2510289A1 — Pharmaceutical compositions and method of treating parkinson's disease

Assigned to Merck Frosst Canada and Co · Expires 2004-07-15 · 22y expired

What this patent protects

This invention is directed to the use of certain pharmaceutical compositions for treating and methods of treating Parkinson s disease. In particular, thi s invention is directed to pharmaceutical compositions for treating and method s of treating Parkinson s disease comprising th…

USPTO Abstract

This invention is directed to the use of certain pharmaceutical compositions for treating and methods of treating Parkinson s disease. In particular, thi s invention is directed to pharmaceutical compositions for treating and method s of treating Parkinson s disease comprising the use of selective cyclooxygena se- 2 inhibitors, such as rofecoxib, etoricoxib, celecoxib and valdecoxib, with and without concomitant use of one or more antiparkinson drugs.

Drugs covered by this patent

Patent Metadata

Patent number
CA2510289A1
Jurisdiction
CA
Classification
Expires
2004-07-15
Drug substance claim
No
Drug product claim
No
Assignee
Merck Frosst Canada and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.